https://www.live-feeds.com/feed/novartis-confirms-9-reported-cases-of-tumors-in-patients-treated-with-zolgensmaContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-confirms-9-reported-cases-of-tumors-in-patients-treated-with-zolgensmahttps://www.live-feeds.com/feed/novartis-confirms-9-reported-cases-of-tumors-in-patients-treated-with-zolgensma#u194225Wed, 11 Nov 2026 14:04:50 +0000Novartis has confirmed nine reported instances of tumors in patients treated with its spinal muscular atrophy gene therapy, Zolgensma. Among these cases, seven were newly disclosed, and two included evidence that the viral delivery vector integrated into patient DNA near the GLI1 oncogene. While advocates sound alarms on social media after learning details from doctors, the US Food and Drug Administration continues to investigate the malignancy risk associated with the treatment, even as its product label still labels the risk as theoretical.Why it mattersZolgensma is a prominent gene therapy